BiotechTube

KHK4827 + Placebo

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Moderate to Severe Plaque Psoriasis

Conditions

Moderate to Severe Plaque Psoriasis

Trial Timeline

Jan 1, 2017 → Aug 14, 2018

NCT ID
NCT02982005

About KHK4827 + Placebo

KHK4827 + Placebo is a phase 3 stage product being developed by Kyowa Kirin for Moderate to Severe Plaque Psoriasis. The current trial status is completed. This product is registered under clinical trial identifier NCT02982005. Target conditions include Moderate to Severe Plaque Psoriasis.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (4)

NCT IDPhaseStatus
NCT04061252Phase 3Completed
NCT03957681Phase 3Completed
NCT02982005Phase 3Completed
NCT01748539Phase 2Completed

Competing Products

20 competing products in Moderate to Severe Plaque Psoriasis

See all competitors
ProductCompanyStageHype Score
Popliteal nerve block including liposomal bupivacaine + Adductor canal nerve block including liposomal bupivacaine + Continuous popliteal nerve block with normal saline + Popliteal nerve block with exclusively unencapsulated bupivacaine + Adductor canal nerve block with exclusively unencapsulated bupivacaine + Continuous popliteal nerve block with unencapsulated bupivacainePacira BiosciencesApproved
80
CT-P13 SC Auto-Injector + Placebo Auto-InjectorCelltrionPhase 3
77
CT-P17 + EU-approved HumiraCelltrionPhase 3
77
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
77
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
77
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
77
PexidartinibDaiichi SankyoPhase 1
33
CS-3150Daiichi SankyoPhase 3
77
tacrolimusAstellas PharmaApproved
85
AlefaceptAstellas PharmaApproved
85
Placebo + SCD-044_Low Dose (Dose 1) + SCD-044_Intermediate Dose (Dose 2) + SCD-044_High Dose (Dose 3)Sun PharmaceuticalPhase 2
52
Tildrakizumab 100 mg + PlaceboSun PharmaceuticalPhase 3
77
Tildrakizumab + Placebo + Tildrakizumab + Tildrakizumab + Tildrakizumab + Etanercept + PlaceboSun PharmaceuticalPhase 2/3
65
Ranirestat + PlaceboEisaiPhase 2/3
65
E6007 + PlaceboEisaiPhase 2
52
KHK4827 + PlaceboKyowa KirinPhase 3
77
KHK4827-Active + KHK4827-PlaceboKyowa KirinApproved
85
KHK4827 + PlaceboKyowa KirinPhase 2
52
Stelara + Bmab1200BioconPhase 3
77
Humira 40 MG in Prefilled Syringe + Hulio 40 MG in Prefilled Syringe / Humira 40 MG in Prefilled SyringeBioconPhase 3
77

Other Products from Kyowa Kirin

KRN23Approved
85
Istradefylline PillApproved
85
MogamulizumabApproved
85
KRN23Approved
85
KHK4827-Active + KHK4827-PlaceboApproved
85